Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?

Exact Sciences (EXAS) has significantly outperformed the broader Medical sector year-to-date, posting a 12% gain compared to the sector's 2% average return, driven by a substantial 134.4% increase in its full-year earnings consensus estimate over the past quarter, earning it a Zacks #1 (Strong Buy) rank. EssilorLuxottica Unsponsored ADR (ESLOY) also demonstrated exceptional performance, returning 50.3% YTD with a positive EPS estimate revision and a Zacks #1 rank, highlighting strong individual stock performance within the medical investment landscape.

Analysis

Exact Sciences (EXAS) has demonstrated significant outperformance within the Medical sector year-to-date, posting a 12% return compared to the sector's average of 2%. This strong performance is underpinned by a substantial 134.4% increase in its full-year earnings consensus estimate over the past quarter, reflecting improved analyst sentiment and a robust earnings outlook. The company currently holds a Zacks Rank #1 (Strong Buy), further reinforcing its positive trajectory.

Similarly, EssilorLuxottica Unsponsored ADR (ESLOY) has shown exceptional strength, delivering a 50.3% year-to-date return, significantly outpacing the broader Medical sector. ESLOY also carries a Zacks Rank #1 (Strong Buy), supported by a 0.5% increase in its current year's consensus EPS estimate over the last three months. While both are in the Medical sector, EXAS is in the Medical - Biomedical and Genetics industry (up 9.3% YTD), and ESLOY is in the Medical - Products industry (up 7.1% YTD), with both stocks outperforming their respective sub-industries.

The strong earnings estimate revisions for EXAS and consistent positive EPS estimate growth for ESLOY suggest fundamental strength and positive momentum. Both companies are positioned as top performers within their respective medical sub-industries, indicating potential for continued solid performance. The high Zacks Ranks for both stocks signal a favorable short-to-medium term outlook based on earnings estimate revisions.

Key Decisions for Investors

• Investors should consider monitoring Exact Sciences (EXAS) and EssilorLuxottica Unsponsored ADR (ESLOY) for continued momentum given their strong year-to-date performance and positive earnings estimate revisions.
• Evaluate the sustainability of earnings growth and analyst sentiment for both companies as key indicators for future performance and potential entry or exit points.
• Assess portfolio allocation to the Medical sector, potentially overweighting sub-industries represented by these strong performers, while acknowledging individual stock-specific risks.